Cargando…

A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression

OBJECTIVES: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Romijn, Amy R, Rucklidge, Julia J, Kuijer, Roeline G, Frampton, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518919/
https://www.ncbi.nlm.nih.gov/pubmed/28068788
http://dx.doi.org/10.1177/0004867416686694
_version_ 1783251552374358016
author Romijn, Amy R
Rucklidge, Julia J
Kuijer, Roeline G
Frampton, Chris
author_facet Romijn, Amy R
Rucklidge, Julia J
Kuijer, Roeline G
Frampton, Chris
author_sort Romijn, Amy R
collection PubMed
description OBJECTIVES: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment response. METHOD: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8 weeks. Data were analysed as intent-to-treat. RESULTS: No significant difference was found between the probiotic and placebo groups on any psychological outcome measure (Cohen’s d range = 0.07–0.16) or any blood-based biomarker. At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group ([Formula: see text] , p = ns). Baseline vitamin D level was found to moderate treatment effect on several outcome measures. Dry mouth and sleep disruption were reported more frequently in the placebo group. CONCLUSIONS: This study found no evidence that the probiotic formulation is effective in treating low mood, or in moderating the levels of inflammatory and other biomarkers. The lack of observed effect on mood symptoms may be due to the severity, chronicity or treatment resistance of the sample; recruiting an antidepressant-naive sample experiencing mild, acute symptoms of low mood, may well yield a different result. Future studies taking a preventative approach or using probiotics as an adjuvant treatment may also be more effective. Vitamin D levels should be monitored in future studies in the area. The results of this trial are preliminary; future studies in the area should not be discouraged.
format Online
Article
Text
id pubmed-5518919
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55189192017-08-02 A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression Romijn, Amy R Rucklidge, Julia J Kuijer, Roeline G Frampton, Chris Aust N Z J Psychiatry Articles OBJECTIVES: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment response. METHOD: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8 weeks. Data were analysed as intent-to-treat. RESULTS: No significant difference was found between the probiotic and placebo groups on any psychological outcome measure (Cohen’s d range = 0.07–0.16) or any blood-based biomarker. At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group ([Formula: see text] , p = ns). Baseline vitamin D level was found to moderate treatment effect on several outcome measures. Dry mouth and sleep disruption were reported more frequently in the placebo group. CONCLUSIONS: This study found no evidence that the probiotic formulation is effective in treating low mood, or in moderating the levels of inflammatory and other biomarkers. The lack of observed effect on mood symptoms may be due to the severity, chronicity or treatment resistance of the sample; recruiting an antidepressant-naive sample experiencing mild, acute symptoms of low mood, may well yield a different result. Future studies taking a preventative approach or using probiotics as an adjuvant treatment may also be more effective. Vitamin D levels should be monitored in future studies in the area. The results of this trial are preliminary; future studies in the area should not be discouraged. SAGE Publications 2017-01-10 2017-08 /pmc/articles/PMC5518919/ /pubmed/28068788 http://dx.doi.org/10.1177/0004867416686694 Text en © The Royal Australian and New Zealand College of Psychiatrists 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Articles
Romijn, Amy R
Rucklidge, Julia J
Kuijer, Roeline G
Frampton, Chris
A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression
title A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression
title_full A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression
title_fullStr A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression
title_full_unstemmed A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression
title_short A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression
title_sort double-blind, randomized, placebo-controlled trial of lactobacillus helveticus and bifidobacterium longum for the symptoms of depression
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518919/
https://www.ncbi.nlm.nih.gov/pubmed/28068788
http://dx.doi.org/10.1177/0004867416686694
work_keys_str_mv AT romijnamyr adoubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT rucklidgejuliaj adoubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT kuijerroelineg adoubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT framptonchris adoubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT romijnamyr doubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT rucklidgejuliaj doubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT kuijerroelineg doubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression
AT framptonchris doubleblindrandomizedplacebocontrolledtrialoflactobacillushelveticusandbifidobacteriumlongumforthesymptomsofdepression